Wells Fargo & Company Lowers Myriad Genetics (NASDAQ:MYGN) Price Target to $6.00

Myriad Genetics (NASDAQ:MYGN) had its target price reduced by equities researchers at Wells Fargo & Company from $6.50 to $6.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 25.39% from the company’s current price.

Other equities analysts also recently issued reports about the stock. Piper Sandler decreased their price target on shares of Myriad Genetics from $9.00 to $8.50 and set an “overweight” rating on the stock in a research note on Tuesday, November 11th. Zacks Research lowered Myriad Genetics from a “hold” rating to a “strong sell” rating in a research report on Monday, January 19th. TD Cowen reiterated a “hold” rating on shares of Myriad Genetics in a research report on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Myriad Genetics in a report on Monday, December 29th. Finally, UBS Group cut their target price on Myriad Genetics from $8.00 to $6.00 and set a “neutral” rating for the company in a research note on Tuesday. Four equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $9.17.

Myriad Genetics Stock Performance

MYGN stock opened at $4.79 on Tuesday. Myriad Genetics has a twelve month low of $3.76 and a twelve month high of $11.89. The firm has a market cap of $446.01 million, a price-to-earnings ratio of -1.21 and a beta of 1.90. The business’s fifty day simple moving average is $5.69 and its two-hundred day simple moving average is $6.62. The company has a quick ratio of 2.12, a current ratio of 2.49 and a debt-to-equity ratio of 0.33.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings results on Monday, February 23rd. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.06. The firm had revenue of $209.80 million during the quarter, compared to analyst estimates of $207.57 million. Myriad Genetics had a negative return on equity of 6.35% and a negative net margin of 44.38%.Myriad Genetics’s quarterly revenue was down .4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.03 earnings per share. Analysts predict that Myriad Genetics will post -0.3 earnings per share for the current year.

Institutional Trading of Myriad Genetics

Several institutional investors and hedge funds have recently bought and sold shares of MYGN. Millennium Management LLC boosted its stake in Myriad Genetics by 41.1% during the fourth quarter. Millennium Management LLC now owns 6,700,158 shares of the company’s stock worth $41,206,000 after buying an additional 1,951,831 shares during the period. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Myriad Genetics by 157.0% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,442,912 shares of the company’s stock worth $17,662,000 after acquiring an additional 1,492,405 shares during the last quarter. Kent Lake PR LLC purchased a new position in shares of Myriad Genetics during the 2nd quarter worth approximately $6,638,000. Federated Hermes Inc. boosted its position in shares of Myriad Genetics by 103,916.0% during the 2nd quarter. Federated Hermes Inc. now owns 1,122,333 shares of the company’s stock worth $5,960,000 after purchasing an additional 1,121,254 shares during the period. Finally, State Street Corp increased its holdings in Myriad Genetics by 19.9% in the 4th quarter. State Street Corp now owns 5,966,567 shares of the company’s stock valued at $36,694,000 after purchasing an additional 990,075 shares during the last quarter. 99.02% of the stock is currently owned by hedge funds and other institutional investors.

More Myriad Genetics News

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Q4 beat and upside guidance — Myriad beat Q4 revenue and EPS expectations and management guided Q1 revenue to rise about 2%–4% year‑over‑year, a key driver for the intraday rally. Myriad Genetics Beats Q4 Expectations, Shares Surge Amid Core Franchise Growth
• Positive Sentiment: Clinical validation boost — Six abstracts presented at ASCO‑GU 2026 reinforced the clinical utility of Myriad’s Precise MRD, Prolaris and MyRisk offerings, which supports longer‑term adoption and addressable market expansion. Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests
• Neutral Sentiment: Analyst view: Hold maintained — TD Cowen reiterated a Hold rating and kept a $7 price target, reflecting a view that valuation looks attractive but uncertainty remains. Balancing Emerging Growth Momentum and Ongoing Uncertainty: Justifying a Hold Amid Attractive Valuation
• Neutral Sentiment: Wells Fargo trimmed its price target to $6.00 and moved to Equal Weight — a modest downgrade in expectations but still implies upside from current levels. Wells Fargo & Company lowers price target
• Negative Sentiment: Sell rating reiterated by Bank of America — an analyst reiterated a Sell rating and $4 price target, highlighting execution and reimbursement risks that could cap upside. Execution and Reimbursement Risks Undermine Myriad Genetics’ Growth Outlook, Justifying Sell Rating
• Negative Sentiment: Margin pressure and product mix headwinds — coverage notes that gross margin slipped in the quarter and mental‑health test volumes declined, which could weigh on near‑term profitability even with top‑line beats. MYGN Stock Up on Q4 Earnings and Revenue Beat, Gross Margin Down

About Myriad Genetics

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.